Disease mechanisms and potential therapeutic strategies in Charcot-Marie-Tooth disease.
Until 10 years ago, the genetic basis of Charcot-Marie-Tooth (CMT) disease was largely unknown. With the finding of an intrachromosomal duplication on chromosome 17 in 1991, associated with the most commonly found subtype CMT1A, and the discovery of a point mutation in the peripheral myelin protein-22 (pmp22) gene in the Trembler mouse in 1992, the groundwork was laid down for a novel chapter in the elucidation of the molecular basis of this large group of peripheral neuropathies. In the meantime, several different genes have been found to be associated with different forms of demyelinating and axonal forms of CMT. In this review, we will summarize what is known today about the genetics of this group of disease which constitute the most common known monogenetic disorder affecting the nervous system in man, the animal models that have been generated, and what we have learned about the underlying disease mechanisms. Furthermore, we will review how this gain of knowledge about CMT may open new avenues to the development of novel treatment strategies.
Young
P
P
Department of Biology, Institute of Cell Biology, Swiss Federal Institute of Technology, ETH-Hönggerberg, 8093, Zürich, Switzerland.
Suter
U
U
D000818:Animals; D002607:Charcot-Marie-Tooth Disease / Q000188:drug therapy / Q000235:genetics* / Q000503:physiopathology; D004195:Disease Models, Animal; D006801:Humans; D009154:Mutation / Q000235:genetics*; D009185:Myelin Proteins / Q000235:genetics* / Q000378:metabolism; D009186:Myelin Sheath / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D010525:Peripheral Nerves / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*
D009185:Myelin Proteins; C073687:PMP22 protein, human; C489545:Pmp22 protein, mouse